1.19
0.85%
+0.01
Dopo l'orario di chiusura:
1.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Stifel Maintains Aclaris Therapeutics (ACRS) Buy Recommendation - MSN
MSN
An analyst sees good growth prospects for Aclaris Therapeutics Inc (ACRS) – Sete News - SETE News
SETE News
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Rises By 19.2% - Defense World
Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 19.2% in April - MarketBeat
MarketBeat
Aclaris Therapeutics Inc (ACRS)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News
US Post News
Balance Sheet Breakdown: Aclaris Therapeutics Inc (ACRS)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX - The Dwinnex
The Dwinnex
Equities Analysts Offer Predictions for Aclaris Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:ACRS) - MarketBeat
MarketBeat
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 943% gain - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Monaco Asset Management SAM Takes $1.03 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
MarketBeat
Leerink Partnrs Comments on Aclaris Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ACRS) - MarketBeat
MarketBeat
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Yahoo Finance
Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital ... - MyChesCo
MyChesCo
Stifel Maintains Aclaris Therapeutics (ACRS) Buy Recommendation - MSN
MSN
Aclaris Therapeutics First Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Simply Wall St
Stock Performance Spotlight: Aclaris Therapeutics Inc (ACRS) Ends the Day at 1.22, Down by -8.96 – DWinneX - The Dwinnex
The Dwinnex
Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital ... - MyChesCo
MyChesCo
Aclaris Therapeutics to Announce Q1 Financial Results and Host Conference Call - MSN
MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
Aclaris Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com South Africa
Investing.com South Africa
Aclaris Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com India
Investing.com India
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
GlobeNewswire
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Yahoo Finance
Yahoo Finance
Investing in Aclaris Therapeutics Inc (ACRS): What You Must Know – Knox Daily - Knox Daily
Knox Daily
Aclaris: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo New Zealand News
Yahoo New Zealand News
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $22.25 Average Price Target from Analysts - MarketBeat
MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $22.25 Average Price Target from Analysts - MarketBeat
MarketBeat
ACRS (Aclaris Therapeutics Inc) has impressive results – US Post News - US Post News
US Post News
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update - GlobeNewswire
GlobeNewswire
Aclaris Therapeutics to Announce Q1 Financial Results and Host Conference Call - MyChesCo
MyChesCo
BML Capital Management LLC Invests $686000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Defense World
ACRS Shares Experience Decline in Value – Knox Daily - Knox Daily
Knox Daily
Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034 by Drug Class, Application and Region - GlobeNewswire
GlobeNewswire
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Has Fallen -4.92% This Week: Buy, Hold, or Sell? - InvestorsObserver
InvestorsObserver
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up - Simply Wall St
Simply Wall St
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Benzinga
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying - Lumen Technologies (NYSE:LUMN), Acla - Benzinga
Benzinga
Aclaris (ACRS) Upgraded to Buy: Here's Why
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Yahoo Finance
Aclaris Therapeutics: A Year of Financial Resilience and Steady Advancements - MyChesCo
MyChesCo
Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations - Yahoo Finance
Yahoo Finance
Capitalizzazione:
|
Volume (24 ore):